This paper analyzes the present situation of intellectualization of hospital outpatient service building,points out its characteristics and disposition requirement,and proposes the design of intellectualized outpatient service.After rectifying outpatient procedure,our hospital designs and practices the new one,which provides humanism service for outpatient.

CENP-Fisacell-cycledependentkinetochoreprotein,whoseexpressionandlocalization patterns are regulated in a cell cycle-dependent manner.CENP-F plays an important role in the development and progress of malignant tumor.The expression of CENP-F is up-regulated in many tumors.It serves as an important marker in cell proliferation.Studies have demonstrated that CENP-F is involved in tumor genesis, progress,invasiveness,relapse and prognosis.CENP-F might be a valuable prognostic marker and potential therapy target in cancer treatment.

In recent years,mTOR inhibitors such as temsirolimus and everolimus are considered to be effective as a new generation of anti-tumor agent.Their efficacies are proven by a number of clinical trials especially in the field of overcoming the drug resistance of tumor cells.But the optimal combination regimen of the mTOR inhibitors and other anti-tumor drugs is still to be validated.

Bisphosphonates are commonly used in patients with breast cancer to reduce skeletal-related events in metastatic disease,mitigate bone loss,and increase bone mineral density.Bisphosphonates can decrease and cleare disseminated tumor cells in bone marrow and circulation tumor cells and then prevent breast cancer relapse and metastases.Bisphosphonates can lighten tumor burden in the breast when administered with neoadjuvant chemotherapy,and improve pathology complete remission rates.Inconsistence is observed in large trials using bisphosphonates in the adjuvant setting of early breast cancer,but survival improvement is mostly seen in postmenopausal patients with low levels of estrogens.

Chemotherapy with or without molecule-targeting agents is the primary choice for patients with unresectable metastatic coloreetal cancer. New treatment strategies like intermittent therapy and maintenance therapy may not inferior to treatment until progression or unacceptable toxicity in maintaining the benefit for patients who responded or had stable disease after the first-line therapy,and also can reduce the drug related side effeets and improve the quality of life.

Medical therapy is the primary choice for patients with advanced biliary tract cancer.Gemcitabine has been proved to be one of the most effective drugs and a standard regimen has been made when combined with cisplatin.Studies of the second line therapy is few.Targeted therapy has a potential to create a new era in the future but needs to be validated in large clinical trials.

Anthracycline-based chemotherapeutic agents were extensively applied to the treatment of breast cancer. The relation of its response to TOP2A gene was proved by a number of clinical studies demonstrating that patients with both HER2 gene amplification and TOP2A gene aberration have a favored outcome,but a consensus was not yet achieved.

With the development of phamacogenomic and molecular biology, it has been revealed that the curative effect of non-small-cell lung cancer (NSCLC) is closely related to tumor molecular markers. Predictive biomarkers in NSCLC patients, including ERCC1, BRCA1, hMLH1, hMSH2, RRM1, β-tubulin, TS,EGFR and K-ras, can predict individual patient's response to chemotherapy or targeted therapy, making individualized therapy be possible.

Poly ADP-Ribose Polymerase(PARP)plays an important role in the detection and repair of DNA damage.Inhibition of the PARP activity in the homologous-recombination defective cancer cell could lead to genomic instability and ultimately cause cell death.In preclinical study PARP inhibitors have demonstrated the capacity of enhancing sensitivity of cancel cells to chemotherapy agents and radiation.PARP inhibitors also showed antitumour potential in early clinical trials as monotherapy or combined with chemotherapy.

Objective To evaluate the effects of antitumor,toxicity and survival of second-line chemotherapy with docetaxel and capecitabine in patients with advanced esophageal squamous cell carcinoma.Methods Thirty eligible patients with measurable lesions received 1-hour intravenous treatment of docetaxel (60 mg/m2 on day 1) plus oral capecitabine (825 mg/m2 twice daily on days 1-14) every 3 weeks for up to 6 cycles.Results Patients received a median of two cycles of treatment (range 2-6).The median follow-up interview was 15.4 months (3.0-31.5 months).Intent-to-treat efficacy analysis demonstrated an overall response rate of 23.3 ％ (0 complete and 7 partial) and stability of 43.3 ％ (13 cases).The median time to progression was 3.0 months (95 ％ CI 1.929-4.071).The median survival was 8.3 months (95 ％ CI6.848-9.752).Severe adverse events (grade 3/4) reported were neutropenia (10 cases),anaemia (5 cases),thrombocytopenia (3 cases),hand-foot syndrome (4 cases),and fatigue (3 cases).Conclusion Docetaxel plus capecitabine have a manageable adverse event profile and promising activity in advance esophageal squamous cell carcinoma as a second-line treatment.